Precision Medicine MoU launching between Pantai Premier Pathology, Astra Zeneca and Prudential Malaysia

BROADENING ACCESS TO GENOMIC TESTING FOR CANCER PATIENTS

New collaboration formed to provide better access to genomic testing, an innovative approach to cancer diagnosis for the targeted treatment of specific cancers

 

KUALA LUMPUR, 4 April 2022 – Battling cancer is extremely challenging because of its impact on the patient’s physical, financial, and mental well-being.

A tripartite collaboration between Prudential Malaysia, AstraZeneca and Pantai Premier Pathology was launched today to pave the way for cancer patients to access genomic testing for a more accurate diagnosis of their cancer based on its genetic profile. Through this collaboration, cancer patients will financially have peace of mind and can look forward to improved treatment outcomes.

This first industry collaboration of this sort was formalised through a signing ceremony between all three parties, witnessed by Yang Berhormat Khairy Jamaluddin, Minister of Health, who also delivered the keynote address.

Representing their organisations at the signing ceremony were Mr. Lim Eng Seong, Chief Executive Officer of Prudential Assurance Malaysia Berhad; Mr. Wan Saifulrizal Wan Ismail, Chief Executive Officer of Prudential BSN Takaful Berhad; Dr. Sanjeev Panchal, Country President of AstraZeneca Malaysia and Mr. Hareeff Muhammed, Chief Executive Officer of Pantai Premier Pathology.

Healthcare professionals have long recognised that cancer behaves differently from one patient to another and therefore there is no one-size-fits-all treatment[1]. Precision medicine is an emerging treatment approach that tailors medical care to individuals based on information acquired from genomic testing which reveals the genetic make-up of the disease. An in-depth understanding of how cancer behaves helps doctors plan specific treatments that may improve survival outcomes and quality of life[2].

Challenges in cancer care are multifaceted, demanding continuous action on a national scale. Many obstacles stand in the way of successful cancer care and this includes access to quality affordable treatment. With the aim to bridge the gap on access and affordability, this tripartite partnership will entail Pantai Premier Pathology providing precision medicine diagnosis through their laboratory, Prudential Malaysia improving affordability to the diagnosis through medical insurance / takaful plans and AstraZeneca supporting by way of education on early diagnosis.

Being the first collaboration of its kind, the partners hope that this initiative will pave the way for other like-minded industry partners such as hospitals and insurance / takaful players to join the coalition to help broaden patients access to quality, affordable cancer care in the country.

Mr. Lim Eng Seong of Prudential Assurance Malaysia Berhad said, “We are delighted to partner with AstraZeneca and Pantai Premier Pathology in this collaboration which synergises our efforts in educating and supporting cancer patients. Prudential Malaysia now extends our coverage to include genomic testing and precision medicine, giving our customers peace of mind that they can be in the best position to focus on their treatment and recovery. This coverage also allows physicians to prescribe clinically suitable treatments and tests from other pharmaceutical companies and laboratories. As their trusted partner in health and protection, we want our customers to face this battle with confidence.”

Mr. Wan Saifulrizal Wan Ismail of Prudential BSN Takaful Berhad said, “We want to do our part in helping the Government with cancer care by making precision medicine accessible and affordable for our customers within all our medical plans. There is a worrying increase in Malaysia’s cancer cases and as the leader in the insurance and takaful industry, we want to do what we can to ensure Malaysians get the best care for a better health outcome. We are proud to collaborate with esteemed partners in this endeavour and optimise health solutions for a healthier nation.”

Dr. Sanjeev Panchal of AstraZeneca said, “We are committed towards playing a vital role in reducing the disease burden in the country by broadening access to healthcare and raising awareness on early screening. Through this partnership with key industry players, we aim to bridge the gaps in cancer care, particularly in the areas of affordability and access to cancer treatment. This industry-first collaboration will enable us to take a step further by making innovative treatments such as precision medicine more affordable and attainable to cancer patients, as well as improve awareness on the importance of early diagnosis.”

Mr. Hareeff Muhammed, Chief Executive Officer of Pantai Premier Pathology said, “Pantai Premier Pathology is constantly keeping up with the demands of modern healthcare, and we are pleased to be one of the pioneers to have a breakthrough service such as genomic testing as part of our cancer care solutions. By being a part of this collaboration, we can continue our mission to make genomic testing for precision medicine more accessible to cancer patients, thereby providing patients with a more comprehensive and affordable suite of healthcare solutions to improve the quality of their health.”

-END-

[1] LaFee, S. (2021, October 13). At Initial Cancer Diagnosis, a Deeply Personalized Assessment. Retrieved from Regents of the University of California: https://health.ucsd.edu/news/releases/Pages/2021-10-13-at-initial-cancer-diagnosis-a-deeply-personalized-assessment.aspx

[2] American Cancer Society. (2020, April 24). Precision or Personalized Medicine. Retrieved from American Cancer Society: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/precision-medicine.html

 

 

Media Coverage:

1. New Straits Times: Click HERE to read more

2. The Star: Click HERE to read more

3. Bernama: Click HERE to read more

4. The Sun Daily: Click HERE to read more

5. Sinar Harian: Click HERE to read more

6. Bernama TV: Click HERE to see more

 

Promo Code Promotion 2022

Wondering Your COVID-19 Antibody Status After Your Vaccination?

Pantai Premier Pathology is currently offering a Promo Code Promotion for Antibody Tests to the general public.

 

Where can you get the Promo Code?

The Promo Code posters are available on Pantai Premier Pathology’s official Facebook and Instagram pages.

Please click the below link to access the official page of Pantai Premier Pathology:

Facebook

Instagram

 

How to redeem the Promo Code?

  1. Go to any Pantai Premier Pathology lab branches. Please refer the Pantai Premier Pathology branches HERE.
  2. Show the Promo Code poster to the lab frontline staff.
  3. Enjoy up to 20% off for any COVID-19 Antibody Test offered.

Medical Genetic Conference Kuala Lumpur 2022 (MGCKL 2022)

`` The Future Is Now: Challenges and Innovative Solutions in Genetics Diagnostics``

About MGCKL 2022

This 3-day conference will address the challenges and innovate solutions in genetic diagnostics and its achievements. More than 20 speakers will be presenting their views and findings in this conference. The conference will provide opportunities and gather pathologists, maternal-fetal specialists, obstetricians and gynecologists, oncologists, respiratory physicians, pediatric neurologists, clinical geneticists, scientists, laboratory technologies, researches, health practitioners, universities and governments to share their knowledge, experiences and achievements in genetics and its related topics.

Participant

3 Days
  • RM 600
  • Entry to all scientific sessions, Wednesday - Friday
  • Entry to the industry booth exhibition, Wednesday - Friday
  • Morning & afternoon teas and lunches, Wednesday - Friday
  • Name badge & conference book (includes all posters and abstracts)

Student

3 Days
  • RM 350
  • Entry to all scientific sessions, Wednesday - Friday
  • Entry to the industry booth exhibition, Wednesday - Friday
  • Morning & afternoon teas and lunches, Wednesday - Friday
  • Name badge & conference book (includes all posters and abstracts)

Calling for abstract !

The conference organizers cordially invite academics, practitioners, scholars, researchers, policy makers of any government to submit their abstracts in MGCKL2022. Abstracts should be submitted online and will be reviewed by two reviewers. We also welcome and highly encourage postgraduate students to present their research proposal or literature review or findings or issues in this conference with very special registration fees.

 

Submission Deadline:
1st August 2022

Pantai Premier Pathology COVID-19 Journey [May 2021]

Take a journey through PPP’s call of duty ensuring safety & peace of mind amidst the ongoing Pandemic. Let us not be complacent in this fight against Covid-19. Stay vigilant & stay safe!

 

In February 2020, Pantai Premier Pathology (PPP) received approval from the Ministry of Health as one of the 4 private labs in Malaysia to start the COVID-19 screening services. In March 2020, a total of 400 samples were run per day using the rtPCR method. These samples were received from various sites including IHH hospitals, GP clinics and corporate clients. In April 2020, PPP expanded its service offering that includes rtPCR and rapid PCR nationwide with an increase in the running capacity to 800 samples per day. A new service, RTK Antigen, was offered nationwide in May 2020, with increased running capacity to 3,500 per day. PPP has also offered support in running MOH samples when required at that time. A total YTD testing of 7.6% of the nationwide capacity at 207,396 tests was achieved in October 2020 with the launch of another service, RTK Antibody testing. In January 2021, PPP opened up another COVID-19 lab located at Pantai Hospital Ampang. After 12 months of providing COVID-19 screening service, PPP contributed to a total of 460,435 testing nationwide in February 2021. More COVID-19 screening labs were started at Gleneagles Medini, Johor Bahru and KLIA, Sepang in March 2021 with overall running capacity up to 8,000 tests per day. PPP has recorded the highest monthly total sample screened to date at 145,181 in one month as at May 2021.

Pantai Premier Pathology Becomes More Internationally Accessible with Accreditation from College of American Pathologists

IHH Healthcare Malaysia’s laboratory arm, Pantai Premier Pathology, is one of only two laboratories in Malaysia to receive accreditation from the College of American Pathologists (CAP).

 

With this latest accreditation, Pantai Premier Pathology will be able to receive samples from Singapore, Brunei, the Philippines, Taiwan, Indonesia and Vietnam for processing, testing and analysis as these countries, among others, require a laboratory to be accredited by CAP for highest quality assurance. More local and international pharmaceutical companies would also now be open to using the services from Pantai Premier Pathology for their clinical trial testing as CAP accreditation is part of the requirements for certain clinical trials.

 

Now, PPP collaborates extensively with pharmaceutical companies in Malaysia and abroad to conduct clinical trial testing and molecular diagnostic services for cancer patients such as Merck, Pfizer, AstraZeneca, Merck Sharp Dohme (MSD), Novartis, Roche, Amgen and Johnson & Johnson (J&J).

 

Having certified with CAP, PPP is driven to provide excellent patient care while fostering and advocating best practices in pathology and clinical laboratory. This value is reputed to elevate PPP’s prestige in the marketplace to leverage an established partnership by attracting patients, doctors and international partners to collaborate with at which they will receive quality services and accurate results with continuous improvement in customer satisfaction.

 

The CAP received from an internationally recognized organization, endorse PPP to retain business through confidence in its high standard management processes known for its advancement in quality for clinical laboratory. Accreditation by the CAP is therefore seen as an attestation to quality laboratory practices and comes with many advantages. Inspections were conducted by expert teams of multi-disciplinary laboratory professionals to ensure PPP’s standards are compliant with the regulations. This detailed and customized evaluation by the expert teams also ensures that test results are always accurate and thus patients’ diagnoses are also accurate.

 

Pantai Premier Pathology is the only laboratory services provider in Malaysia with four accreditations, including from Joint Commission International, ISO 15189 and the Malaysian Society for Quality in Health. Established in 2016, the laboratory offers diagnostic tests for Pre-Natal, Post-Natal, Haemato-Oncology, Solid Tumour and Infectious Diseases, including COVID-19 testing.

 

 

Media Coverage

The Star:

https://www.thestar.com.my/business/business-news/2021/06/08/ihhs-laboratory-gets-recognition

 

The Sun Daily:

https://www.thesundaily.my/local/ihh-s-laboratory-arm-receive-accreditation-from-cap-NA7938708

 

The Edge Markets:

https://www.theedgemarkets.com/article/ihhs-laboratory-arm-receive-accreditation-cap